Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.
T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. The company has a collaboration partnership with AbCellera Biologics Inc. for a project in antibody discovery.
Pipeline and products
Autolus is developing AUTO1, a programmed T cell therapy targeting CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.
Pre-clinical and clinical data from an ongoing Phase I CARPALL trial of AUTO1 were published in Nature Medicine in 2019. In the Phase I clinical trial 86% of the pediatric ALL patients (n=14) showed molecular complete remission after a single dose with a median duration of remission of 7.4 months and no severe cytokine release syndrome.
AUTO2 is a programmed T cell therapy with two targets, for the treatment of relapsed or refractory multiple myeloma. AUTO2 is in PhaseI/II clinical trials as of 2019.
AUTO3 is a dual-targeting programmed T cell therapy for treating relapsed or refractory diffuse large B-cell lymphoma, which is in Phase I/II clinical trials as of 2019.
AUTO4 is a programmed T cell therapy for treatment of peripheral T-cell lymphoma and is in Phase I/II clinical trials as of 2019.
AUTO6 is a programmed T cell therapy for treatment of neuroblastoma.
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Nature Medicine (2019)
Authors from Autolus and various cancer research institutes in London, UK presented pre-clinical and clinical data on the programmed T cell therapy called AUTO1.
Autolus Therapeutics raises a $80,000,000 series C round from Syncona Investment Management, Nextech Invest, Cormorant Asset Management, Arix Bioscience plc and Woodford Investment Management.
Autolus Therapeutics was founded.
Dr. Christian Martin Itin
Dr. Jim Faulkner, PhD
Head of Manufacturing
Dr. Louise Holliday
Head of Intellectual Property
Dr. Martin Pulé
Mr. Christopher Vann
Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
Autolus Therapeutics plc
Biotech to create 170 jobs, invest $28M in new Rockville HQ
New CAR T-cell therapy for leukemia associated with fewer harmful side effects
September 4, 2019
Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.